Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus

Su Jin Park; Young Jae Si; Jihye Kim; Min Suk Song; Se mi Kim; Eun Ha Kim; Hyeok il Kwon; Young Il Kim; Ok Jun Lee; Ok Sarah Shin; Chul Joong Kim; Eui Cheol Shin; Young Ki Choi

doi:10.1016/j.virol.2016.08.010

Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus

Su Jin Park, Young Jae Si, Jihye Kim, Min Suk Song, Se mi Kim, Eun Ha Kim, Hyeok il Kwon, Young Il Kim, Ok Jun Lee, Ok Sarah Shin, Chul Joong Kim, Eui Cheol Shin, Young Ki Choi

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10–40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD₅₀ of H5N8 virus, with the exception of mice vaccinated with 3.5 μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.

Original language	English
Pages (from-to)	36-43
Number of pages	8
Journal	Virology
Volume	498
DOIs	https://doi.org/10.1016/j.virol.2016.08.010
Publication status	Published - 2016 Nov 1

Bibliographical note

Funding Information:
This research was supported by Korea Healthcare Technology R&D Project funded by the Ministry of Health (Grant No: A103001 ).

Publisher Copyright:
© 2016 Elsevier Inc.

Keywords

ADCC
Cross-protection
H5N8
HPAI H5N1
Vaccine

ASJC Scopus subject areas

Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virol.2016.08.010

Cite this

@article{175bd867fd0541468217e8b4805c5b6d,

title = "Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus",

abstract = "To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10–40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD50 of H5N8 virus, with the exception of mice vaccinated with 3.5 μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.",

keywords = "ADCC, Cross-protection, H5N8, HPAI H5N1, Vaccine",

author = "Park, {Su Jin} and Si, {Young Jae} and Jihye Kim and Song, {Min Suk} and Kim, {Se mi} and Kim, {Eun Ha} and Kwon, {Hyeok il} and Kim, {Young Il} and Lee, {Ok Jun} and Shin, {Ok Sarah} and Kim, {Chul Joong} and Shin, {Eui Cheol} and Choi, {Young Ki}",

note = "Funding Information: This research was supported by Korea Healthcare Technology R&D Project funded by the Ministry of Health (Grant No: A103001 ). Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.virol.2016.08.010",

language = "English",

volume = "498",

pages = "36--43",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus

AU - Park, Su Jin

AU - Si, Young Jae

AU - Kim, Jihye

AU - Song, Min Suk

AU - Kim, Se mi

AU - Kim, Eun Ha

AU - Kwon, Hyeok il

AU - Kim, Young Il

AU - Lee, Ok Jun

AU - Shin, Ok Sarah

AU - Kim, Chul Joong

AU - Shin, Eui Cheol

AU - Choi, Young Ki

PY - 2016/11/1

Y1 - 2016/11/1

N2 - To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10–40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD50 of H5N8 virus, with the exception of mice vaccinated with 3.5 μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.

AB - To investigate cross-protective vaccine efficacy of highly-pathogenic avian influenza H5N1 viruses against a recent HPAI H5N8 virus, we immunized C57BL/6 mice and ferrets with three alum-adjuvanted inactivated whole H5N1 vaccines developed through reverse-genetics (Rg): [Vietnam/1194/04xPR8 (clade 1), Korea/W149/06xPR8 (clade 2.2), and Korea/ES223N/03xPR8 (clade 2.5)]. Although relatively low cross-reactivities (10–40 HI titer) were observed against heterologous H5N8 virus, immunized animals were 100% protected from challenge with the 20 mLD50 of H5N8 virus, with the exception of mice vaccinated with 3.5 μg of Rg Vietnam/1194/04xPR8. Of note, the Rg Korea/ES223N/03xPR8 vaccine provided not only effective protection, but also markedly inhibited viral replication in the lungs and nasal swabs of vaccine recipients within five days of HPAI H5N8 virus challenge. Further, we demonstrated that antibody-dependent cell-mediated cytotoxicity (ADCC) of an antibody-coated target cell by cytotoxic effector cells also plays a role in the heterologous protection of H5N1 vaccines against H5N8 challenge.

KW - ADCC

KW - Cross-protection

KW - H5N8

KW - HPAI H5N1

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84982128156&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2016.08.010

DO - 10.1016/j.virol.2016.08.010

M3 - Article

C2 - 27543757

AN - SCOPUS:84982128156

SN - 0042-6822

VL - 498

SP - 36

EP - 43

JO - Virology

JF - Virology

ER -

Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this